Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Zenzedi Generic Name & Formulations
Legal Class
CII
General Description
Dextroamphetamine sulfate 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg, 30mg; tabs.
Pharmacological Class
CNS stimulant.
How Supplied
Tabs—100
Manufacturer
Generic Availability
NO
Zenzedi Indications
Indications
Attention deficit hyperactivity disorder.
Zenzedi Dosage and Administration
Adults and Children
<3yrs: not recommended. Avoid late evening doses; give first dose upon awakening and additional doses at 4–6hr intervals. Individualize. 3–5yrs: initially 2.5mg daily, may increase by 2.5mg/day at weekly intervals. ≥6yrs: initially 5mg once or twice daily; may increase by 5mg/day at weekly intervals; usual max 40mg/day.
Zenzedi Contraindications
Contraindications
Advanced arteriosclerosis. Symptomatic cardiovascular disease. Moderate to severe hypertension. Hyperthyroidism. Glaucoma. History of drug abuse. Agitation. During or within 14 days of MAOIs. Hypersensitivity to sympathomimetics.
Zenzedi Boxed Warnings
Boxed Warning
Potential for abuse. Misuse may cause sudden death and serious cardiovascular events.
Zenzedi Warnings/Precautions
Warnings/Precautions
Abuse potential (monitor). Known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease: not recommended. Hypertension. Heart failure. Recent MI. Arrhythmias. Assess cardiovascular status. Psychosis. Bipolar disorder; screen for risk before initiation. Depression. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for worsening of aggressive behavior or hostility. Discontinue if seizure disorders, serotonin syndrome occur. Evaluate for tics or Tourette's syndrome prior to therapy. Peripheral vasculopathy including Raynaud's phenomenon; monitor for digital changes. Monitor HR, BP, growth in children. Reevaluate periodically. Write ℞ for smallest practical amount. Pregnancy (Cat.C). Nursing mothers: not recommended.
Zenzedi Pharmacokinetics
See Literature
Zenzedi Interactions
Interactions
See Contraindications. Hypertensive crisis with MAOIs (including linezolid, IV methylene blue). Increased risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's wort), CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine, ritonavir); consider alternatives; if needed, initiate with lower doses and monitor. Potentiated by alkalinizers (eg, sodium bicarbonate, acetazolamide). Antagonized by acidifiers, chlorpromazine, haloperidol, lithium. May potentiate effects of TCAs, sympathomimetics, norepinephrine, meperidine. May antagonize adrenergic blockers, antihistamines, antihypertensives, veratrum alkaloids. May delay absorption of phenobarbital, phenytoin, ethosuximide. Convulsions with propoxyphene overdose and amphetamines. May interfere with urinary steroid test.
Zenzedi Adverse Reactions
Adverse Reactions
Palpitations, tachycardia, BP increase, overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, motor/phonic tics, Tourette's syndrome, dry mouth, unpleasant taste, diarrhea, constipation, anorexia, weight loss, urticaria, impotence, libido changes, prolonged erections, rhabdomyolysis; visual disturbances.
Zenzedi Clinical Trials
See Literature
Zenzedi Note
Not Applicable
Zenzedi Patient Counseling
See Literature
Zenzedi Generic Name & Formulations
Legal Class
CII
General Description
Dextroamphetamine sulfate 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg, 30mg; tabs.
Pharmacological Class
CNS stimulant.
How Supplied
Tabs—100
Manufacturer
Generic Availability
NO
Zenzedi Indications
Indications
Narcolepsy.
Zenzedi Dosage and Administration
Adult
Avoid late evening doses. 5–60mg daily in divided doses.
Children
Avoid late evening doses; give first dose upon awakening and 1–2 more doses 4–6hrs apart. <6yrs: not recommended. 6–12yrs: initially 5mg daily; may increase by 5mg/day at weekly intervals. ≥12yrs: initially 10mg daily; may increase by 10mg/day at weekly intervals.
Zenzedi Contraindications
Contraindications
Advanced arteriosclerosis. Symptomatic cardiovascular disease. Moderate to severe hypertension. Hyperthyroidism. Glaucoma. History of drug abuse. Agitation. During or within 14 days of MAOIs. Hypersensitivity to sympathomimetics.
Zenzedi Boxed Warnings
Boxed Warning
Potential for abuse. Misuse may cause sudden death and serious cardiovascular events.
Zenzedi Warnings/Precautions
Warnings/Precautions
Abuse potential (monitor). Known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease: not recommended. Hypertension. Heart failure. Recent MI. Arrhythmias. Assess cardiovascular status. Psychosis. Bipolar disorder; screen for risk before initiation. Depression. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for worsening of aggressive behavior or hostility. Discontinue if seizure disorders, serotonin syndrome occur. Evaluate for tics or Tourette's syndrome prior to therapy. Peripheral vasculopathy including Raynaud's phenomenon; monitor for digital changes. Monitor HR, BP, growth in children. Reevaluate periodically. Write ℞ for smallest practical amount. Pregnancy (Cat.C). Nursing mothers: not recommended.
Zenzedi Pharmacokinetics
See Literature
Zenzedi Interactions
Interactions
See Contraindications. Hypertensive crisis with MAOIs (including linezolid, IV methylene blue). Increased risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's wort), CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine, ritonavir); consider alternatives; if needed, initiate with lower doses and monitor. Potentiated by alkalinizers (eg, sodium bicarbonate, acetazolamide). Antagonized by acidifiers, chlorpromazine, haloperidol, lithium. May potentiate effects of TCAs, sympathomimetics, norepinephrine, meperidine. May antagonize adrenergic blockers, antihistamines, antihypertensives, veratrum alkaloids. May delay absorption of phenobarbital, phenytoin, ethosuximide. Convulsions with propoxyphene overdose and amphetamines. May interfere with urinary steroid test.
Zenzedi Adverse Reactions
Adverse Reactions
Palpitations, tachycardia, BP increase, overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, motor/phonic tics, Tourette's syndrome, dry mouth, unpleasant taste, diarrhea, constipation, anorexia, weight loss, urticaria, impotence, libido changes, prolonged erections, rhabdomyolysis; visual disturbances.
Zenzedi Clinical Trials
See Literature
Zenzedi Note
Not Applicable
Zenzedi Patient Counseling
See Literature
